Halofuginone
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Halofuginone: From Unknown Indication to Diabetic Retinopathy
One-Sentence Summary
Halofuginone is a febrifugine derivative with no approved indication data currently on file and no market presence in Germany. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy and diabetic retinopathy, but this prediction is currently supported by no clinical trials and no published literature — it rests entirely on theoretical mechanistic reasoning.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no approved indications on file) |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.46% |
| Evidence Level | L5 |
| Germany Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available in structured form (Data Gap). However, based on known pharmacology, halofuginone is a febrifugine derivative reported to (1) inhibit type I collagen synthesis and block TGF-β/Smad3 signaling, giving it antifibrotic activity historically explored in fibrotic diseases such as scleroderma; (2) exhibit antiangiogenic activity; and (3) inhibit prolyl-tRNA synthetase, triggering an amino acid starvation response that modulates Th17 differentiation and inflammation.
Diabetic retinopathy — particularly the severe nonproliferative stage — involves TGF-β-driven extracellular matrix accumulation, fibrovascular proliferation, and inflammatory pathways. There is theoretical overlap between these disease mechanisms and halofuginone's known antifibrotic and antiangiogenic properties, which is likely why TxGNN assigned a high prediction score.
This mechanistic overlap remains purely theoretical. No original indication is on file to anchor a repurposing rationale, the drug is not marketed anywhere referenced in this evidence pack, and no clinical or preclinical evidence directly links halofuginone to diabetic retinopathy. The prediction should be treated as a hypothesis-generating signal only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Germany Market Information
Halofuginone has no market authorizations on file (0 authorizations, not marketed).
Safety Considerations
Please refer to the package insert for safety information. Detailed warnings, contraindications, and drug interaction data are not currently available for this compound (marked as Data Gap in the source evidence, classified as Blocking severity — this must be resolved before any safety evaluation can proceed).
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is based solely on TxGNN's model output (L5, no supporting clinical or literature evidence) for a drug that has no documented original indication, no market presence, and no available safety data — none of the minimum requirements for even a preliminary safety assessment are met.
To proceed, the following is needed:
- TFDA/regulatory label data — warnings, contraindications (currently Blocking data gap)
- Confirmed mechanism of action from DrugBank or primary literature
- Confirmation of original approved indication(s), if any exist in other jurisdictions
- Preclinical or clinical evidence specifically linking halofuginone to diabetic retinopathy or related fibrovascular/ocular pathology
- Basic human pharmacokinetic and safety data, given the drug is not currently marketed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.